# Efficacy and Safety of Autologous Peptide-induced Active Immunity in AML Maintenance Therapy

> **NCT07551037** · PHASE1 · RECRUITING · sponsor: **Fujian Medical University Union Hospital** · enrollment: 90 (estimated)

## Conditions studied

- Acute Myeloid Leukemia
- Personalized Active Immunotherapy
- Maintenance Therapy

## Interventions

- **BIOLOGICAL:** Active Immunotherapy
- **OTHER:** after 6 courses of routine consolidation chemotherapy
- **OTHER:** during 6 courses of routine consolidation chemotherapy

## Key facts

- **NCT ID:** NCT07551037
- **Lead sponsor:** Fujian Medical University Union Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-01
- **Primary completion:** 2026-09-01
- **Final completion:** 2026-09-01
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07551037

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07551037, "Efficacy and Safety of Autologous Peptide-induced Active Immunity in AML Maintenance Therapy". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07551037. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*